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The last 30 years have seen major changes in attitude toward patients with cerebral metastases. This paper aims to outline the
major landmarks in this transition and the therapeutic strategies currently used. The controversies surrounding control of brain
disease are discussed, and two emerging management trends are reviewed: tumor bed radiosurgery and salvage radiation.
1.Introduction
1.1. Background. Brain metastases are the most common
form of brain cancer and exceed the number of primary
brain tumors by at least fourfold, with an estimated 98,000–
170,000 new cases of brain metastases per year in North
America [1, 2]. These ﬁgures will further rise as a result of
an ageing population, increasing use of improved diagnostic
imaging and advancements in systemic and local cancer
therapies. The primary tumors most likely to metastasize to
the brain are located in the lung (50%), breast (15–25%),
skin (melanoma) (5–20%), colon-rectum, and kidney [3, 4].
In addition, most other malignant tumors can metastasize
to the brain. In up to 15% of patients, the primary site is
unknown.
The diagnosis of brain metastases (BM) is devastat-
ing for both patients and caregivers as evidenced by the
heavy burden of disease and signiﬁcant impact on quality
of life (QOL). Clinical manifestations can include focal
neurological deﬁcits, seizures, raised intracranial pressure,
and alteration in cognition, personality, and ultimately
functional status. Untreated, patients with BM will typically
live less than two months [5].
Patients harbouring BM present a therapeutic challenge
to clinicians. This is primarily due to the heterogeneity in
cancer type and extent, patient demographics and clinical
status, and treatment history and options. To better under-
stand the factors inﬂuencing survival, a recursive partition-
ing analysis (RPA) of data from three Radiation Therapy
Oncology Group (RTOG) prospective brain metastases trials
was performed identifying 3 classes of patients based on age,
performance status, systemic disease control, and presence
of extracranial metastases (Table 1)[ 6]. These classes predict
median survival (7.1, 4.2, and 2.3 months for classes I, II,
andIIIpatients,resp.)andsuggestthatmanyRPAIIIpatients
will beneﬁt little from aggressive treatment. More aggressive
strategies are recommended in younger patients with con-
trolled systemic cancer, minimal extra-cranial metastases,
and high-performance status.
Based on a review of more than four thousand BM
patients, the disease-speciﬁc graded prognostic assessment
(DS-GPA) can produce survival estimates better tailored to
the primary malignancy [7]. In some cancers, additional
factors will be of prognostic importance (hormone receptor
status for breast cancer and number of brain metastases
in lung cancer, melanoma, and renal cell carcinoma) while
in others performance status will dominate prognosis (gas-
trointestinal malignancies) [8].
The ongoing expansion in the number and complexity
of therapeutic options seen over the past three decades
has added further intricacy to the management of BM
patients. Treatment decisions must therefore be tailored to
each individual, based on a complex array of patient- and
tumour-speciﬁc characteristics, as no single algorithm is
appropriate for every patient. Close collaboration is required
between general medical and radiation oncologists, neuro-
oncologists,andneurosurgeonsinamultidisciplinarysetting
where multiple treatment modalities can be oﬀered.2 International Journal of Surgical Oncology
Table 1: RTOG (RPA) recursive partitioning analysis [6] (modiﬁed
by age).
Class Variables
Class I KPS ≥ 70, controlled primary tumor,
metastases to brain only, age < 76 years
Class II
KPS ≥ 70, but uncontrolled primary tumor,
age < 76 years
KPS ≥ 70, primary controlled, but metastases
to brain and other sites, age < 76 years
Class III KPS < 70
Finally, there is a lack of consensus amongst practitioners
on the optimum treatment strategy and it is often the experi-
ence of the local treating team that governs decision making.
This trend is underpinned by persistent controversies and
limitations in the data supporting management guidelines.
Whilst accepted medical practice, many of the treatment
regimes prescribed are not founded on rigorous prospective
data. More evidence-based driven treatment paradigms are
required. This review aims to discuss the existing literature,
some of the key on-going controversies, and emerging trends
surrounding local control (LC) of BM.
2.TherapeuticStrategiesand
Supporting Evidence
The last 30 years have seen important changes in the
management of brain metastases. Below is a timeline dis-
playing the major landmarks and some of the notable related
publications (Figure 1).
2.1. Corticosteroids. The palliative use of corticosteroids in
patients harbouring cerebral metastases is necessary for
symptom control as it aids in alleviating peritumoral edema
[9, 10]. However, the dose and duration of corticosteroid use
isvariable.Althoughrecommendedforshort-termsymptom
control, patients often remain on prolonged regimens with
related complications. These complications are well known
and can negatively impact quality of life due to the associated
adverse eﬀects such as myopathy, hyperglycemia, weight
gain, immune suppression, insomnia, emotional lability, and
occasional severe psychiatric disturbances.
2.2. Whole-Brain Radiation Therapy. Although only studied
in a 48-patient trial from the pre-CT scan era, whole-
brain radiation therapy (WBRT) has been the mainstay
of metastatic brain tumour therapy for decades. Following
WBRT, overall survival is typically 3-4 months. The goals
of WBRT include relief of symptoms from existing BM and
prevention of future BM. Common North American regi-
mens use parallel-opposed megavoltage beams to deliver 20–
37.5Gyin5–15dailyfractionsover1–3weeks.Acutecompli-
cations include encephalopathy, cerebral edema, nausea and
vomiting, alopecia, dermatitis, mucositis, otitis externa, and
fatigue. Late complications can include optic and otic toxic-
ities, endocrinopathies, and decline in neurocognitive func-
tion. Although potentially debilitating, the real incidence of
severe radiation encephalopathy is poorly documented [11].
In a study published in 1989, a dementia rate of 11% was
reported in a series of 47 patients. Of particular note, four
of these patients received a high dose per fraction (5 or
6Gy) while the other patient received a concurrent radiation
sensitizer [12]. The 15 patients who received less than 3Gy
fractions did not develop dementia. Various authors now
agree that the delayed late-radiation injury to the brain may
be overstated and less relevant with respect to outcome [13].
However,aspatientssurvivelongerwiththeirprimarycancer
long-term adverse outcomes of WBRT are of signiﬁcant con-
cern[14]andanumberoftrialshaveandcontinuetoaddress
these issues [15]. Without such prospective investigations it
is diﬃcult to discern the contributing eﬀect that multiple
systemic therapies can have on cognitive function.
WBRT is often used alone in RPA class III patients whose
main alternative treatment option is best supportive care.
In this setting, both overall response rate and neurologic
improvement range from 50% to 60% [16, 17]. WBRT can
also be used in conjunction with local treatment (surgery
or stereotactic radiosurgery) in RPA class I/II patients
whose alternative is local treatment alone or local treatment
combined with systemic treatment.
2.3. Surgery Alone or in Combination with WBRT. Surgical
excision of cerebral metastases is often used in patients with
RPA class I/II, harbouring single lesions, and minimal or
controlledsystemicdisease[18]. Thegoalsof surgeryinclude
establishment of a diagnosis, LC in noneloquent locations,
and rapid relief of symptoms (e.g., mass eﬀect, hemorrhage,
hydrocephalus). Currently, surgery involves intraoperative
image guidance, microsurgical techniques, perioperative
neurologic monitoring, and awake craniotomy with cortical
mapping. These and other reﬁnements [19, 20]h a v er e s u l t e d
in signiﬁcant reduction in postoperative complications
which can include infection, neurologic deﬁcits (including
potential impairments of cognition, speech, movement,
sensation, vision, hearing, and coordination), cerebral hem-
orrhage, and/or infarction, the incidence of which have
been reduced to under 5% [21, 22]. Postoperative mortality
has been reduced to less than 1% [23]. Unlike inﬁltrating
primary brain tumours, BMs are usually well demarcated
from surrounding brain parenchyma. This increases the
ability to achieve a gross total resection with a minimum of
morbidity, especially new neurological deﬁcits.
A classical and much quoted randomized controlled trial
(RCT) by Patchell et al. [24] investigated the value of adding
surgery to WBRT. They demonstrated that resection of a
single BM leads to improved overall survival (OS; driven
by increased LC), QOL, and LC compared to WBRT alone
[24].SimilarresultsweredemonstratedinanotherRCT[25].
However, only a quarter to a third of BM patients have
a single lesion [26, 27] and of these nearly half are not
suitable for surgery (inaccessibility of the tumor, extensive
systemic disease, unﬁt for surgery, etc.). Thus, only 15%
of all BM patients are surgical candidates. Furthermore,
surgical resection does not eradicate microscopic disease in
the operative bed nor does it address disease elsewhere in
the brain. A follow-up RCT led by Patchell showed thatInternational Journal of Surgical Oncology 3
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Figure 1: Timeline showing some of the landmarks in the management of brain metastases and related publications.
the addition of adjuvant WBRT following surgical resection
reduced recurrence at the surgical site compared to surgery
alone [28]. Moreover, adjuvant WBRT following surgery
prevented subsequent development of distant BMs and
reducedneurologicaldeathwhencomparedtosurgeryalone.
OSandQOLwerereportedasnotaﬀected[28]raisingdoubt
as to the value of WBRT in preserving QOL and functional
independence.
2.4. Stereotactic Radiosurgery Alone or in Combination
with WBRT. Stereotactic radiosurgery (SRS) is a technique
whereby multiple convergent beams deliver high-energy X-
rays, gamma rays, or protons to a discrete radiographically
deﬁned target [29]. Due to the rapid fall-oﬀ of dose outside
the target volume, the radiation dose delivered to the
normal brain tissue distant from the tumour is clinically
insigniﬁcant. The advantages of SRS are the relative ease of
tolerability for patients and the ability to treat deep-seated,
surgically inaccessible lesions as well as those traditionally
considered radioresistant such as melanoma [30] and renal
cell carcinoma [31]. A number of SRS devices are in clinical
use, including the Gamma Knife (GK, Elekta AB, Stock-
holm) dedicated linear accelerators such as the CyberKnife
(Accuray, Sunnyvale, CA; mounted on a robotic arm) or the
Novalis Tx (BrainLAB/Varian Medical Systems, Palo Alto,
CA/Munich,Germany;multi-leafcollimatorprovidingbeam
shaping) as well are various modiﬁed conventional linear
accelerators. Radiosurgery has revolutionized the treatment
of brain metastases since its ﬁrst use in North America in the
late 1980s [32] and, after more than 30 years of experience
[33], has established itself as a valid therapeutic option
providing a high degree of LC for small (≤3u pt o4 c m )
metastases [34].
T h ea b i l i t yo fu p f r o n tS R St oi m p r o v es u r v i v a lh a sb e e n
demonstrated prospectively relatively recently [35–38]. A
literature review by the American Society for Therapeutic
RadiologyandOncology(ASTRO)summarizedtheavailable
data according to the level of evidence [35] .B a s e do nL e v e l
I–III evidence, for selected patients with single, small (up
to 4cm) brain metastases (up to 3 lesions and 4 in one
randomized trial), the addition of SRS boost to WBRT
improves brain control as compared with WBRT alone.
Thereare twoprospective randomized studies thathave been
published in extenso on the subject [36, 38]. The strongest
evidence comes from the Radiation Therapy Oncology
Group (RTOG) 95–08 trial [36], which randomized 164
patients to WBRT and SRS boost versus 167 patients to
WBRT alone. Patients with one to three newly diagnosed
brain metastases were included. The brain metastases could
be a maximum diameter of 4cm for the largest lesion and
the additional lesions could not exceed 3cm. For these three
randomized trials, local brain control at 1 year ranged from
82% to 92% in the SRS boost arm versus 0%–71% in the
whole-brain alone arm.
Treatment with radiosurgery alone appears to result
in the same overall survival as the combination of SRS
and WBRT. However, local and distant brain control is
signiﬁcantly poorer with omission of upfront WBRT (Level
I–III evidence) [36, 39]. Despite this, there is a recent trend
toward withholding adjuvant WBRT from initial treatment
and deferring it until other treatments have failed. The
concerns are long-term neurotoxicity (especially in longer
surviving patients), the availability of eﬀective salvage treat-
ments, and the fact that adjuvant WBRT does not translate
into a prolonged OS or have an impact on preservation
of performance status or functional independence [14, 40].
It seems that in patients with a limited number of brain
metastases(onetothreemetastases),whoareinitiallytreated
with either radiosurgery or surgery, WBRT can be withheld
if serial imaging for followup is performed [15]. There
remains a paradox that patients without active systemic
diseaseandgoodperformancestatusmaybebothmorelikely
to beneﬁt from WBRT and more likely to be harmed by its
late toxicities. Patients with a poor performance status or
active systemic disease may either die before developing new4 International Journal of Surgical Oncology
metastases or reseed their brain from uncontrolled extra-
cranial tumors.
2.5. Multiple Metastases. Some of the nihilism that sur-
rounded the management of oligometastases in the past still
persists with multiple metastases patients. This is likely due
to the perceived poor outcomes despite available treatments
andthehighincidenceofconcurrent,activesystemicdisease.
There is a subset of patients, however, who have treated
or controlled systemic disease and have maintained good
neurologic function primarily due to small tumor size.
Traditionally, fractionated WBRT to a dose of approximately
30Gy has been administered. Surgical resection has been
oﬀered rarely to these patients, because the morbidity of
resection in multiple brain locations was believed to be
excessive, and the risk for developing additional tumors
perceived to be high. Stereotactic radiosurgery potentially
provides answers to both of the aforementioned problems.
Radiosurgery can be performed in most brain loca-
tions, irrespective of regional brain function. Accordingly,
radiosurgery can be used to treat multiple metastases
in one setting [41–43]. In a retrospective study of 323
patients, Chang et al. analyzed the eﬃcacy of radiosurgery in
treating patients with various numbers of brain metastases
[42]. When assessing patient survival and progression-free
survival times as a function of the number of BMs, they
reported no statistical diﬀerence between survival times after
radiosurgery.Althoughremotediseaseprogressionwasmore
frequent in patients with >15BMs, there was no statistical
diﬀerence in local control rates. These ﬁndings identiﬁed
SRS as a treatment option for local control of metastatic
lesions and raised the notion that SRS might oﬀer improved
survival in patients with multiple metastatic brain lesions.
In a separate retrospective study, Bhatnagar et al. devised a
recursive partitioning analysis of 205 patients with four or
more BM who were treated with SRS in one setting [41].
SRS was used alone or in conjunction with WBRT, or after
failure of WBRT. With a median marginal radiosurgery dose
of 16Gy and median total treatment volume of 6.8cc, they
identiﬁed two distinct cohorts of patients. Patients with a
total treatment volume of <7cc and <7 brain metastases
(4–6) were found to have extended survival following SRS.
Those patients with >7cc and >7BMs had a signiﬁcantly
poorer survival following SRS. These studies conﬁrmed a
role for SRS in the treatment of patients with multiple BMs,
and identiﬁed a subgroup of patients with improved survival
following SRS. Like conventional surgery, however, SRS is a
focal treatment and its role remains limited by the risk of
development of further tumors outside the initial irradiation
volumes.
3. Emerging Trends in Treatment of BM
With the complex needs of patients with brain metastases,
therapeutic options evolve based on clinical judgement and
case series. Many strategies have yet to be supported by
prospective RCT’s. The authors believe that two emerging
treatment paradigms will soon integrate the mainstream and
thus warrant further clinical studies.
3.1. Radiotherapy to the Surgical Bed. The postoperative
delivery of WBRT for patients with BM aims to sterilize
residual disease in the tumor bed as well as other sites of
occult disease in the brain. Reviewing the RCT data from
Patchell et al., in the absence of WBRT, 46% of patients with
an MRI conﬁrmed complete resection had a recurrence in
the original site at a median of 27 weeks. The addition of
high-dose WBRT (50.4Gy) decreased this recurrence to 10%
with a time to recurrence of ≥52 weeks [28]. This series, as
mostothers,didnotcensurepatientsforLCatthetimeoflast
imagingleadingtofailurerateunderestimations.Inaddition,
few physicians use such high doses of WBRT in clinical
practice either because of resource limitations or for fear
of neurocognitive eﬀects. Finally, complete resection is not
always conﬁrmed by immediate post-operative MR imaging.
With these caveats, the actual 1-2 year local recurrence rate is
likely often higher in clinical practice.
Stereotactic radiosurgery to the surgical bed in addition
to or without WBRT is an emerging trend in the treatment
of brain metastases. A retrospective review carried out at
the McGill University Health Center, Montreal, Canada
(MUHC) of patients treated with surgery followed by WBRT
revealed an actuarial rate of local recurrence of 67% at 2
years [44]. A retrospective series from Rades et al. [45, 46]
compared 2 groups of patients with RPA class I to II disease
with 1-2 resectable brain metastases: resection plus WBRT
and same treatment plus a fractionated boost to the tumor
bed (5 fractions of 3Gy or 5 fractions of 2Gy each). In this
series,theboost improvedbothLC(2-yearLCaftercomplete
resection88%versus32%,P<0.001)andoverallsurvival(1-
year OS 66% versus 41%, P<0.001). In a 5-year experience
at the MUHC using WBRT plus a tumor bed SRS boost of
10Gy in 44 patients, the actuarial 2-year LC was 91%. The
median survival was 17 months, and with a median followup
of 10 months, only 11% developed new metastases [47–49].
Without the SRS boost, the 1- and 2-year actuarial LC rates
were 52% and 33%, respectively, statistically worse than with
tumor bed SRS (P<0.001) and in keeping with the data of
Rades et al. [45, 46].
Some institutions advocate radiosurgery alone as adju-
vant treatment. Three recent retrospective studies have
described the use of SRS or fractionated stereotactic radio-
therapy following surgery without WBRT. Soltys et al.
reporteda1-yearactuarialLCrateof79%withnodeathssec-
ondary to neurologic causes in a series of 72 patients treated
atStanfordUniversity[50].Inaseriesof40patients,Mathieu
et al. reported a crude LC of 73% (2-year actuarial LC of
60%) [51]. One-ﬁfth of patients had only a partial resection.
Do et al. demonstrated that an actuarial 1-year LC rate was
82%in30patients,19(63%)ofwhichdevelopedrecurrences
in new intracranial sites [52]. WBRT was administered only
as salvage treatment in 14 of the 30 patients.
TheconcernwithtumorbedSRSaloneisthatSRSislim-
ited by the size of the tumor cavity and prone to geographic
miss. Some groups have advocated the inclusion of a 2mm
margin around the tumor cavity to improve LC [50]. As
previously discussed, WBRT has a proven eﬀect in reducing
the occurrence of new brain metastases. In Patchell’s study,
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to 14% [28]. Aoyama et al. demonstrated a reduction from
64 to 42% with no diﬀerence in toxicity [39]. In addition,
the above studies looking at SRS ± WBRT demonstrated
greater local control rates with intact brain metastases. It
seems reasonable to expect that in a similar fashion, the
combination of SRS and WBRT would show improved local
control at the surgical bed. Moreover, WBRT eliminates any
risk of complete marginal miss from diﬃculties in deﬁning
a proper post-operative target. The use of a reduced dose
of SRS opens this option to patients with large tumors and
lesions approximating critical structures. These patients can
thus be treated without compromising dose intensity.
In summary, post-operative intracranial failure most
commonly occurs in the tumor bed, despite the use of adju-
vant WBRT. Although evidence suggests that postoperative
SRS provides increased LC, a prospective trial comparing
this strategy to WBRT alone has not been carried out and
is the subject of a current National Cancer Institute trial
(NCT00003320). If the number of published series can be
usedasanindicator,tumorbedSRSaloneisbeingusedmore
and more commonly. If this strategy can provide equivalent
LC to WBRT with less neuro-cognitive toxicity, its adoption
will grow rapidly.
3.2. Salvage Following Initial Treatment Failure. Advances in
chemotherapeutic agents for systemic cancer have improved
patient survival and overall prognosis. As the number of
patients with prolonged survival rises, and the use of upfront
WBRT decreases, an increase in a subgroup of patients
with BM who have failed initial treatment and developed
recurrence is likely. Although previously neglected, this
growing subgroup merits speciﬁc studies to determine the
optimumtreatmentstrategytoextendsurvivalandminimize
morbidity.
At our institution, over a third of the eligible patient
population undergo upfront SRS alone. The therapeutic
strategies oﬀered to these patients continue to evolve but
ﬁnding Level 1 evidence to guide physicians remains chal-
lenging, as studies in this area are very limited.
Brain relapses comprise not only lesions that have
progressed locally following initial treatment but also new
lesions that have developed at a distance or a combination
of the two. In this context, surgical resection is often not
appropriate and not indicated as more than two-thirds of
patients have multiple brain metastases and large tumors
a r es c a r c ea sc l o s e rM R If o l l o w u pa l l o w se a r l yd e t e c t i o no f
new metastases. Current chemotherapy regimens or small
molecule inhibitors used for targeted therapy of systemic
cancer are typically not eﬀective for BM as the blood-
brain barrier limits bioavailability in the tumour tissue
[53]. Nonsurgical salvage treatment options include WBRT
for WBRT-na¨ ıve patients, repeat WBRT, salvage SRS, or a
combination of radiation modalities.
3.2.1. Salvage WBRT. Although Salvage WBRT alone is a
widely accepted traditional approach at most institutions,
there are no studies that evaluate its use in patients whose
initial management did not include WBRT, in other words
salvage WBRT after failure of initial treatment with SRS.
Conversely, the use of repeat WBRT in patients who have
failed previous treatment with WBRT has been reported
but its use remains controversial and doubts persist as to
the therapeutic ratio [54–57]. Largely retrospective data
show improvement in neurologic function in 31–42% of
patients, median duration of response of 2.5 months, and
median survival of 4-5 months following reirradiation with
20–25Gy over multiple fractions. The strongest predictors of
a favourable outcome following re-irradiation were a good
performance status and a good response to initial treatment.
Late complications are largely unreported but proponents
argue that these need to be balanced by the likely occurrence
of neurological deterioration if lesions are left untreated
[56].
3.2.2. Salvage Radiosurgery. Salvage radiosurgery as deﬁned
by the use of SRS to treat brain relapses is being oﬀered on
an individual basis and is in many cases accepted as sole
treatment. Indeed, this indication was at the very origin of
the use of SRS for BM [58]. Although its role at the time of
progressive brain metastases previously treated with either
whole-brain radiotherapy or SRS alone has not been fully
elucidated, there is evidence to suggest that it provides good
LC thus extending BDFS [59]. However, there are theoretical
concerns of higher rates of radiation necrosis associated with
repeat SRS at local failure with the consequent increased risk
of neurological deﬁcits.
A number of retrospective case series exist analyzing
salvageSRSinpatientswhoseinitialmanagementwasWBRT
along [59–62]. These studies date back to the early 1990s
where Loeﬄer et al. showed 100% LC in 21 lesions [59]. In
one of the larger series of the subsequent decade, No¨ el et al.
[62] reported 1- and 2-year LC rates of 91 and 84% with a
median survival of 7.8 months in 54 patients whose median
interval between the end of WBRT and salvage SRS was 9
months. One- and 2-year new brain event-free survival rates
were 65% and 57%, respectively. Although 24% of patients
developed new metastases, none of the patients died from
cerebral cause, and only 5% of the treated lesions recurred
with 28% of patients being still alive at 2 years. Only 7% of
patients developed complications including mild headaches
and alopecia. In a larger more recent study, Chao et al.
showed an overall survival of 9.9 months following salvage
SRSin 111 patients [60]. LC was68 and 59% at 1 and 2 years,
respectively, with 25 and 31% of patients developing local
and distant recurrence, respectively. Only 3.6 % of patients
developed complications (radiation necrosis in 2 patients,
seizures in 1, and severe fatigue in 1). One prospective study
showed a median survival of 6 months from salvage SRS
with LC of 19 treated lesions [61]. Time to progression was
not reported and 75% of the lesions eventually recurred.
Although predictive factors were not consistent in the
literature, the interval between WBRT and SRS seem to
predict overall survival.
A few studies examine the use of salvage SRS after initial
treatment with SRS [63–66]. Two of these studies present
survival data from the date of salvage SRS [63, 64]. Kwon
et al. presented a series of 43 patients who underwent salvage
SRS in which median survival from the time of SRS to6 International Journal of Surgical Oncology
recurrent/progressive disease was 32 weeks and the LC rate
of retreated lesions at 6 months was 91% [64]. Multivariate
analysis revealed that RPA class was the only predictor for
overall survival. In the case series by Chen et al., of 45
patients, median survival from the time of SRS for recurrent
brainmetastaseswas28weeks[63].The1-yearfreedomfrom
progression rate was 94%. Both authors noted that repeated
SRS may extend survival at least as long as the ﬁrst SRS inter-
vention had. Multivariate regression analysis failed to reveal
factorspredictive of survival. Unfortunately, these studies are
retrospective and the reported results are subject to selection
bias. No comparison is made with other competing strate-
gies, making the evidence class II and III [67]. In addition,
predictivefactorsareinconsistent.Nevertheless,theyprovide
compelling support for repeat or salvage SRS being eﬀective
in treating locally progressive or new lesions after initial SRS.
Arguably, this strategy should be considered in favourable
RPA class patients in order to minimize morbidity, maximize
patient quality of life and perception of disease burden [60],
and to reduce cost [68–71]. Prospective trials are needed to
determine the clinical value and compare SRS and WBRT
salvage modalities at the time of local or distant failure.
The goal of brain metastases management is to mini-
mize morbidity and mortality, improve patient quality of
life, and reduce associated treatment costs. In an era of
healthcare budget constraints, it is imperative that clinicians
adopt ﬁscally responsible standards to guide their practice.
Several reports have examined the treatment outcomes
and cost-eﬀectiveness of current management paradigms.
In a retrospective study, Metha and colleagues assessed
the survival and quality of life outcome data for patients
with solitary brain metastasis, who were randomized to
receive WBRT, surgery + WBRT, or radiosurgery alone [69].
When comparing the relative cost ratios of surgery and
radiosurgery, and analyzing the cost-eﬀectiveness (cost per
year of median survival) of each modality, radiosurgery
yielded greater survival and functional independence versus
surgery or WBRT alone. Rutigliano et al. reported similar
ﬁndings in a separate retrospective study [70]. More recently,
Lee et al. examined the outcomes and cost-eﬀectiveness of
treating 156 patients with multiple brain metastases, ran-
domized to receive radiosurgery or WBRT [68]. The follow-
up time in this study was 3.3 years. The mortality rate for
radiosurgery-treatedpatients,withmultiplebrainmetastases
(2–5 lesions) and a good initial KPS score, was found to
be signiﬁcantly better. Radiosurgery also resulted in better
posttreatment KPS scores, improved quality of life, and
higher cost-eﬀectiveness when compared to WBRT. These
ﬁndings highlight the need for prospective clinical trials to
comprehensively study the clinical and economic eﬃcacy of
various treatment modalities, especially in a time of increas-
ing healthcare costs and signiﬁcant budget constraints.
4. Conclusions
Over the last three decades a major shift in the philosophy
guiding the treatment of patients with brain metastases
has occurred. The traditional nihilistic expectation of rapid
neurological decline and inevitable neurological demise is no
longer acceptable, and the focus has moved from palliation
to achieving sustained brain disease control, systemic disease
control, and preserved neurological function. Thus, with a
variety of aggressive treatment options available to them,
patients can now beneﬁt not only from longer overall
survival but also extended brain disease-free survival and
improved quality of life. These parameters and others
including the prolongation of functional independent status,
reduction in burden of focal neurological deﬁcits, neu-
rocognitive preservation, and freedom from seizures have
now become established treatment goals and have taken
o v e ro v e r a l ls u r v i v a la sp r i m a r ye n d p o i n t si nm a j o rb r a i n
metastases trials.
With current management strategies, patients with lim-
ited brain metastases are often more likely to succumb from
their systemic disease than from their brain tumour(s) [28].
Continual progress in systemic cancer treatments has led to
a steady increase in patient survival and overall prognosis.
Paradoxically, as control of systemic disease improves, the
occurrence of brain metastases and its associated neurolog-
ical morbidity and mortality will increase.
The management of brain metastases has seen a
paradigm shift from palliation toward aggressive interven-
tion to achieve control of brain disease. Following surgical
resection, adjuvant WBRT has been shown to decrease death
due to neurological causes. However, more recent data has
highlighted the potential beneﬁt of more aggressive local
control measures involving surgical resection and SRS in
addition to WBRT. Radiosurgery alone, surgical resection
with adjuvant SRS, and advanced chemotherapeutic agents
have been increasingly used amidst concerns of the potential
neurotoxicity of WBRT.
Following surgery, intracranial failure most commonly
occurs in the tumor bed, despite WBRT. Postoperative SRS
boost to the tumor cavity may provide acceptable local
control without many of the toxicities of WBRT. The eﬃcacy
of this strategy remains to be tested in a comparative
prospective trial. Optimum management strategies at the
time of failure remain unclear and include salvage WBRT,
salvage SRSs or a combination of the two.
In summary, although much progress has been made
in the last 3 decades, numerous challenges lay ahead in
establishing evidence-based guidelines in this challenging
group of patients. The ﬁeld of neuro-oncology is witnessing
an exciting evolution in management of brain metastases.
The future holds great promise and opportunity to carry
out focused clinical investigations to demonstrate eﬃcacy
of our treatment paradigms. Proposed management goals
will not only aim to increase overall survival and brain
disease-free survival, but also to improve quality of life and
prolong functional independent status whilst minimizing
neurological deﬁcit.
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